Thesis (Ph. D.)--University of Washington, 1990. / Vita. Includes bibliographical references (leaves [270]-296).

No description available.

Thesis (M. Res. (Med.))--University of Hong Kong, 2006.

Thèse d'exercice : Médecine. Cardiologie et pathologies vasculaires : Université de Nantes : 2005. / Bibliogr. f. 107-120 [244 réf.].

published_or_final_version / Medicine / Master / Master of Philosophy

Thesis (M. Res.(Med.))--University of Hong Kong, 2007.

Thesis (Ph.D.)--Boston University

The endotracheal (ET) route for the administration of selected drugs has been proposed as an effective alternate route of drug administration during emergency situations when an intravenous (IV) line cannot be established. Lidocaine may be beneficial in the treatment of ventricular fibrillation (VF) resulting from acute myocardial infarction, although this hypothesis has not been confirmed in the literature. The efficacy of lidocaine in the treatment of ventricular fibrillation due to acute coronary artery ligation was examined, as well as the use of the endotracheal route as an alternative to IV injection. Rabbits were anesthetized with sodium pentobarbital or halothane, intubated with an endotracheal tube, and animals receiving pentobarbital were mechanically respired. Ventricular fibrillation was produced by occlusion of the left circumflex coronary artery, or by subsequent reperfusion of ischemic myocardium. Endotracheal administration of 2mg/Kg lidocaine (2mg/ml in normal saline) resulted in lower peak plasma lidocaine concentrations initially compared with IV injection, but more sustained levels in the therapeutic range for lidocaine (p<0.05). Administration of lidocaine either IV or ET during ventricular fibrillation resulted in a significant increase (p<0.05) in plasma lidocaine concentrations during the first minute compared with controls. During ventricular fibrillation there was no significant difference between plasma lidocaine levels following IV or ET administration. Administration of lidocaine 2mg/Kg endotracheally (in normal saline) during VF resulted in a significant decrease in the duration of fibrillation compared with untreated and normal saline controls (p <0.001). / Pharmaceutical Sciences, Faculty of / Graduate

BACKGROUND: AF is a growing epidemic in the United States that will continue to worsen as risk factors become more prevalent in the population. The arrhythmia often persists asymptomatically before presenting as a stroke or when the disease has progressed to cause permanent cardiac restructuring. The gold standard for diagnosis is ECG. The current treatment consists of rate control, rate control, and stroke prevention with anticoagulation. LITERATURE REVIEW: Recent studies have shown that screening for AF does result in an increase in AF diagnosis. A current gap in literature remains regarding if that increase in AF diagnosis leads to a stroke reduction in the screened population. PROPOSED PROJECT: The proposed project is a randomized control trial that will compare AF diagnosis in a control group to a group that is screened for AF using a 30-day cardiac monitor. The statistical analysis will reveal if there is a reduction in stroke and other cardiac sequelae in the screened group compared to the control group. CONCLUSION/SIGNIFICANCE: Should the study reveal that screening for AF in an at-risk population reduces the risk of stroke, it could assist the USTF in addressing the gap in literature required to either recommend for or against AF screening in the United States.

La fibrillation auriculaire (FA) est une pathologie très répandue qui affectera au sein de la population occidentale, une personne sur quatre au cours de sa vie. À partir d'extraits d'appendices auriculaires chez des patients, nous avons mesuré les niveaux d'expression de gènes et des protéines de communication intercellulaire des connexines (Cx) 40 et 43 et de marqueurs inflammatoires (TNF-a, 1TL-Ip\ IL-6, IL-8 et le Nf-icb) par PCR en temps réel, par immunobuvardage de type Western et par immunoessai de type sandwich à l'aide d'un système Bio-Plex®. Les résultats quantitatifs ont été confrontés aux données cliniques afin d'identifier des corrélations entre les résultats et certaines conditions pathologiques comme le syndrome métabolique (SM), le diabète de type II (DU) et la FA post-opératoire (FAPO). Notre étude n'a pas démontré de relation entre la FAPO et l'expression des marqueurs inflammatoires et des protéines de communication intercellulaire. Une sous-expression de la Cx40 chez les individus atteints de SM et de DU et une surexpression de IL-1P chez le groupe de DU ont été observées. La FAPO est une pathologie complexe qui émerge d'une combinaison de variables physiologiques mais aussi opératoires souvent imprévisibles.